The A2 rating reflects AbbVie’s large global scale and strong competitive positions in immunology, oncology, neuroscience and ...
Big Pharma delivered strong Q4 2025 results, with most companies beating revenue and EPS expectations and providing generally solid 2026 guidance. Eli Lilly solidified its leadership in obesity and ...
The stock market is divided, with the Nasdaq and S&P 500 breaking support but many sectors thriving. Google and Amazon AI ...
Select products from Pfizer, Eli Lilly and others will be sold at a discount, although the lower costs won’t be felt by many ...